Operating Expenses Summary of Bionime Corporation

Bionime Corporation's latest annual operating expenses in 2023 was 673.63 Million TWD , down -13.54% from previous year.
Bionime Corporation's latest quarterly operating expenses in 2024 Q2 was 243.74 Million TWD , up 27.28% from previous quarter.
Bionime Corporation reported a annual operating expenses of 843.12 Million TWD in annual operating expenses 2022, up 15.75% from previous year.
Bionime Corporation reported a annual operating expenses of 728.39 Million TWD in annual operating expenses 2021, up 3.36% from previous year.
Bionime Corporation reported a quarterly operating expenses of 191.49 Million TWD for 2024 Q1, down -17.35% from previous quarter.
Bionime Corporation reported a quarterly operating expenses of 169.56 Million TWD for 2023 Q3, down -5.74% from previous quarter.

Annual Operating Expenses Chart of Bionime Corporation (2023 - 2009)

Historical Annual Operating Expenses of Bionime Corporation (2023 - 2009)

Year	Operating Expenses	Operating Expenses Growth
2023	673.63 Million TWD	-13.54%
2022	843.12 Million TWD	15.75%
2021	728.39 Million TWD	3.36%
2020	704.72 Million TWD	-9.88%
2019	781.97 Million TWD	15.39%
2018	677.7 Million TWD	23.81%
2017	547.35 Million TWD	6.89%
2016	512.08 Million TWD	0.11%
2015	511.5 Million TWD	14.86%
2014	445.31 Million TWD	-7.79%
2013	482.91 Million TWD	-13.04%
2012	555.34 Million TWD	7.28%
2011	517.65 Million TWD	30.24%
2010	397.45 Million TWD	30.69%
2009	304.12 Million TWD	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q2	243.74 Million TWD	27.28%
2024 Q1	191.49 Million TWD	-17.35%
2023 Q3	169.56 Million TWD	-5.74%
2023 FY	728.98 Million TWD	-13.54%
2023 Q1	183.18 Million TWD	-27.0%
2023 Q4	231.7 Million TWD	36.65%
2023 Q2	179.89 Million TWD	-1.79%
2022 Q2	205.39 Million TWD	15.13%
2022 FY	843.12 Million TWD	15.75%
2022 Q1	178.4 Million TWD	-0.76%
2022 Q3	208.38 Million TWD	1.46%
2022 Q4	250.93 Million TWD	20.42%
2021 Q4	179.77 Million TWD	-10.9%
2021 FY	728.39 Million TWD	3.36%
2021 Q1	193.34 Million TWD	6.86%
2021 Q2	153.51 Million TWD	-20.6%
2021 Q3	201.76 Million TWD	31.42%
2020 Q1	159.26 Million TWD	-37.55%
2020 Q2	172.82 Million TWD	8.52%
2020 Q3	191.69 Million TWD	10.91%
2020 FY	704.72 Million TWD	-9.88%
2020 Q4	180.93 Million TWD	-5.61%
2019 FY	781.97 Million TWD	15.39%
2019 Q1	113.86 Million TWD	-39.87%
2019 Q2	209.56 Million TWD	84.05%
2019 Q3	203.52 Million TWD	-2.88%
2019 Q4	255.02 Million TWD	25.3%
2018 FY	677.7 Million TWD	23.81%
2018 Q4	189.37 Million TWD	1.28%
2018 Q3	186.97 Million TWD	15.15%
2018 Q2	162.37 Million TWD	18.82%
2018 Q1	136.64 Million TWD	-23.06%
2017 Q4	177.61 Million TWD	33.44%
2017 Q3	133.1 Million TWD	16.55%
2017 FY	547.35 Million TWD	6.89%
2017 Q2	114.2 Million TWD	-6.73%
2017 Q1	122.43 Million TWD	-12.43%
2016 FY	512.08 Million TWD	0.11%
2016 Q4	139.81 Million TWD	3.55%
2016 Q3	135.02 Million TWD	7.38%
2016 Q2	125.74 Million TWD	12.76%
2016 Q1	111.5 Million TWD	-20.52%
2015 FY	511.5 Million TWD	14.86%
2015 Q3	141.41 Million TWD	18.22%
2015 Q4	140.29 Million TWD	-0.79%
2015 Q2	119.61 Million TWD	8.56%
2015 Q1	110.18 Million TWD	-10.38%
2014 Q4	122.94 Million TWD	25.61%
2014 Q1	111.98 Million TWD	-2.99%
2014 Q2	112.51 Million TWD	0.47%
2014 FY	445.31 Million TWD	-7.79%
2014 Q3	97.87 Million TWD	-13.01%
2013 Q3	119.14 Million TWD	-9.89%
2013 Q1	116.11 Million TWD	-16.99%
2013 FY	482.91 Million TWD	-13.04%
2013 Q4	115.43 Million TWD	-3.12%
2013 Q2	132.21 Million TWD	13.87%
2012 Q1	133.6 Million TWD	-1.36%
2012 Q4	139.88 Million TWD	-3.8%
2012 Q3	145.39 Million TWD	7.21%
2012 Q2	135.62 Million TWD	1.51%
2012 FY	555.34 Million TWD	7.28%
2011 Q1	109.31 Million TWD	8.23%
2011 FY	517.65 Million TWD	30.24%
2011 Q4	135.44 Million TWD	-5.39%
2011 Q3	143.15 Million TWD	10.35%
2011 Q2	129.73 Million TWD	18.67%
2010 Q4	101 Million TWD	-3.26%
2010 Q2	101.67 Million TWD	12.51%
2010 Q3	104.41 Million TWD	2.7%
2010 Q1	90.36 Million TWD	0.0%
2010 FY	397.45 Million TWD	30.69%
2009 FY	304.12 Million TWD	0.0%

Peer Operating Expenses Comparison of Bionime Corporation

Name	Operating Expenses	Operating Expenses Difference
Nang Kuang Pharmaceutical Co., Ltd.	495.65 Million TWD	-35.909%
Maxigen Biotech Inc.	274.24 Million TWD	-145.633%
SciVision Biotech Inc.	312.85 Million TWD	-115.318%
Pegavision Corporation	1.68 Billion TWD	60.073%
Visco Vision Inc.	522.44 Million TWD	-28.938%

Global Stocks Search

Bionime Corporation (4737.TW)

Operating Expenses Summary of Bionime Corporation

Annual Operating Expenses Chart of Bionime Corporation (2023 - 2009)

Historical Annual Operating Expenses of Bionime Corporation (2023 - 2009)

Peer Operating Expenses Comparison of Bionime Corporation